For an 80-year-old man with bladder cancer, should the first-line chemotherapy be gemcitabine plus cisplatin or etoposide plus cisplatin?

Gemcitabine Plus Cisplatin is the Standard First-Line Chemotherapy for This 80-Year-Old Patient with Bladder Cancer

For an 80-year-old man with bladder cancer requiring first-line chemotherapy, gemcitabine plus cisplatin (GC) is the established standard of care, NOT etoposide plus cisplatin. Etoposide plus cisplatin is not a recommended regimen for bladder cancer in any major guideline.

Guideline-Based Recommendations

First-Line Standard Regimens

The NCCN guidelines consistently identify gemcitabine plus cisplatin as a Category 1 recommendation for first-line treatment of advanced/metastatic bladder cancer 1, 2, 3, 4. This designation reflects the highest level of evidence and uniform consensus. The 2024 NCCN guidelines have evolved to prioritize enfortumab vedotin plus pembrolizumab as the preferred first-line option 4, but when this combination is not available or appropriate, GC remains a standard choice.

Etoposide plus cisplatin is NOT listed as a recommended regimen in any NCCN guideline version for bladder cancer 1, 2, 3, 4. This combination is primarily used for small cell lung cancer, not urothelial carcinoma.

Evidence Supporting Gemcitabine Plus Cisplatin

The GC regimen achieved Category 1 status based on a landmark randomized trial showing equivalence to MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) with similar survival but significantly less toxicity 1, 2, 1. The 5-year survival update confirmed non-inferiority: overall survival 13.0% vs 15.3% for MVAC, with fewer toxic deaths (1% vs 3%) 1.

Special Considerations for an 80-Year-Old Patient

Age-Specific Data

Real-world evidence specifically in octogenarians shows that GC is feasible and effective in patients ≥80 years 5, 6:

• In a retrospective study of 12 patients aged 80-84 years with metastatic urothelial carcinoma treated with GC, the objective response rate was 42%, median time to progression was 6 months, and median overall survival was 14 months 5
• Grade 3-4 toxicities were primarily hematological (anemia 33%, neutropenia 58%, thrombocytopenia 50%), with no severe non-hematological toxicities 5
• A more recent study of 30 patients aged ≥80 years showed 40% objective response rate and 76.7% disease control rate, though 70% required dose reduction and 46.7% discontinued treatment due to toxicity 6

Critical Caveats for Elderly Patients

Performance status and renal function are the key determinants, not chronological age alone 2, 3, 1:

• Cisplatin eligibility requires: adequate renal function (GFR ≥60 mL/min), good performance status, and absence of significant cardiac disease or hearing impairment 2, 3
• If cisplatin-ineligible, carboplatin may be substituted for cisplatin in the GC regimen, though with potentially reduced efficacy 2, 3, 1
• For carboplatin plus gemcitabine in cisplatin-ineligible patients, response rates drop to 26-42% with increased toxicity in those with renal impairment 2, 1

Dose Modifications

Proactive dose reductions should be strongly considered in octogenarians 6, 7:

• A 2025 study found that no patients completed 6 cycles at full dose, and only 2% tolerated >80% relative dose intensity of both drugs 7
• Starting with reduced doses may minimize treatment interruptions and side effects while maintaining palliative benefit 7
• Myelosuppression frequently necessitates dose reduction (70% of patients) or treatment discontinuation (47%) 6

Alternative Options if Cisplatin-Ineligible

If this 80-year-old patient has GFR <60 mL/min, ECOG performance status ≥2, or significant comorbidities, consider:

1. Carboplatin plus gemcitabine (Category 2B) 2, 3
2. Checkpoint inhibitor monotherapy (pembrolizumab or atezolizumab) if PD-L1 positive 2, 3
3. Enfortumab vedotin plus pembrolizumab if available (now preferred first-line regardless of cisplatin eligibility) 8, 4

Why Not Etoposide Plus Cisplatin?

The only comparative data for etoposide plus cisplatin in bladder cancer comes from a non-small cell lung cancer trial that included it as a control arm against GC 9. In that NSCLC study, GC showed superior response rate (33% vs 14%, p=0.01) and longer time to progression (5 months vs 4.1 months, p=0.015) compared to etoposide plus cisplatin 9. There is no evidence supporting etoposide plus cisplatin for bladder cancer, and it is not mentioned in any bladder cancer treatment guideline.

Practical Algorithm

For this 80-year-old man:

1. Assess cisplatin eligibility: Check GFR, performance status, cardiac function, hearing
2. If cisplatin-eligible: Use gemcitabine 1000-1250 mg/m² days 1,8 + cisplatin 70-100 mg/m² day 1, every 21-28 days 1, 2, 9
   • Consider starting at reduced doses (e.g., 75-80% of standard) given age 6, 7
3. If cisplatin-ineligible: Use carboplatin AUC 4-5 + gemcitabine, or consider checkpoint inhibitor if PD-L1 positive 2, 3
4. Monitor closely: Expect dose reductions in 70% and potential early discontinuation 6
5. Re-evaluate after 2-3 cycles: Continue if responding/stable, maximum 6 cycles 2, 3